Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss

Eledon Pharmaceuticals

13/05/2026 21:21

Overview

US biotech firm's Q1 net loss widened yr/yr, impacted by non-cash warrant liability loss

Company highlighted positive tegoprubart results in islet and kidney transplantation studies

FDA granted Orphan Drug designation to tegoprubart for liver transplantation

Outlook

Company expects FDA guidance on Phase 3 trial design for tegoprubart in kidney transplantation in 2026

Eledon plans to initiate several new clinical trials for tegoprubart in 2026

Company expects current cash and investments to fund operations into 2Q 2027

Result Drivers

CLINICAL MILESTONES - Co cited positive data updates in kidney and islet cell transplantation studies for tegoprubart as key achievements in the quarter

REGULATORY DESIGNATION - FDA granted Orphan Drug designation to tegoprubart for prevention of allograft rejection in liver transplantation

Company press release: ID:nGNX2FbTf9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$39.03 mln
Q1 Income from Operations
-$21.18 mln
Q1 Operating Expenses
$21.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $8.50, about 117.9% above its May 12 closing price of $3.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)